[{"id":"73f525e9-88d1-49d4-a2a6-9faf82456aae","acronym":"","url":"https://clinicaltrials.gov/study/NCT05262491","created_at":"2022-11-08T18:28:24.724Z","updated_at":"2025-02-25T15:35:30.552Z","phase":"Phase 1","brief_title":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor","source_id_and_acronym":"NCT05262491","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" TACSTD2","pipe":"","alterations":" ","tags":["TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab brengitecan (BL-B01D1)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 02/14/2022","start_date":" 02/14/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-12-18"},{"id":"3ab273df-ad84-463e-809d-9cbd385707ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT05990803","created_at":"2023-08-14T14:10:30.823Z","updated_at":"2025-02-25T15:36:27.652Z","phase":"Phase 2","brief_title":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies","source_id_and_acronym":"NCT05990803","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab brengitecan (BL-B01D1) • danvilostomig (SI-B003)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 11/06/2023","start_date":" 11/06/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-10-24"},{"id":"20c1edcd-7b1a-4a0e-a322-cf7af957ea0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06008054","created_at":"2023-08-23T15:11:10.298Z","updated_at":"2025-02-25T15:36:29.034Z","phase":"Phase 2","brief_title":"A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors","source_id_and_acronym":"NCT06008054","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab brengitecan (BL-B01D1) • danvilostomig (SI-B003)"],"overall_status":"Recruiting","enrollment":" Enrollment 376","initiation":"Initiation: 11/16/2023","start_date":" 11/16/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-09-25"},{"id":"6478b2e2-568c-410e-9877-3d989cfbdd71","acronym":"","url":"https://clinicaltrials.gov/study/NCT05880706","created_at":"2023-05-30T14:05:24.607Z","updated_at":"2025-02-25T15:36:16.707Z","phase":"Phase 2","brief_title":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05880706","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • izalontamab brengitecan (BL-B01D1)"],"overall_status":"Recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-08-07"},{"id":"6bf2b896-e018-4a72-8241-0b41b1b66f40","acronym":"","url":"https://clinicaltrials.gov/study/NCT06118333","created_at":"2023-11-07T20:13:25.871Z","updated_at":"2025-02-25T15:36:37.862Z","phase":"Phase 3","brief_title":"A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT06118333","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • capecitabine • izalontamab brengitecan (BL-B01D1)"],"overall_status":"Recruiting","enrollment":" Enrollment 368","initiation":"Initiation: 12/04/2023","start_date":" 12/04/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-07-18"},{"id":"8ffc43aa-6147-4c99-a983-e627e958440f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06042894","created_at":"2023-09-21T16:11:01.150Z","updated_at":"2025-02-25T15:36:32.414Z","phase":"Phase 2","brief_title":"A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer","source_id_and_acronym":"NCT06042894","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab brengitecan (BL-B01D1) • danvilostomig (SI-B003)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 12/12/2023","start_date":" 12/12/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-07-18"},{"id":"36893d7d-86e8-48f0-a407-ed95796d7b18","acronym":"","url":"https://clinicaltrials.gov/study/NCT05948865","created_at":"2023-07-17T14:08:58.925Z","updated_at":"2024-07-02T16:35:05.955Z","phase":"Phase 1","brief_title":"A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05948865","lead_sponsor":"Conjupro Biotherapeutics, Inc.","biomarkers":" EGFR • KRAS","pipe":" | ","alterations":" EGFR mutation • KRAS wild-type • RAS wild-type","tags":["EGFR • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SYS6010"],"overall_status":"Recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/06/2023","start_date":" 06/06/2023","primary_txt":" Primary completion: 06/13/2025","primary_completion_date":" 06/13/2025","study_txt":" Completion: 12/12/2025","study_completion_date":" 12/12/2025","last_update_posted":"2024-05-03"},{"id":"d9fd809b-eb43-4044-9ecf-63c36ff9e599","acronym":"","url":"https://clinicaltrials.gov/study/NCT04695847","created_at":"2021-01-19T20:49:32.993Z","updated_at":"2025-02-25T16:10:59.679Z","phase":"Phase 1","brief_title":"M1231 in Participants With Solid Tumors","source_id_and_acronym":"NCT04695847","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" EGFR • MSI • MUC1","pipe":" | ","alterations":" MSI-H/dMMR • EGFR expression","tags":["EGFR • MSI • MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M1231"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 01/13/2021","start_date":" 01/13/2021","primary_txt":" Primary completion: 06/23/2023","primary_completion_date":" 06/23/2023","study_txt":" Completion: 06/23/2023","study_completion_date":" 06/23/2023","last_update_posted":"2023-07-07"},{"id":"3a17035a-fef8-4bd4-80a2-7c5f2ca1ed3f","acronym":"Intellance1","url":"https://clinicaltrials.gov/study/NCT02573324","created_at":"2021-01-18T12:28:11.635Z","updated_at":"2024-07-02T16:35:48.205Z","phase":"Phase 3","brief_title":"A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification","source_id_and_acronym":"NCT02573324 - Intellance1","lead_sponsor":"AbbVie","biomarkers":" EGFR • MGMT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • EGFRvIII mutation","tags":["EGFR • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • EGFRvIII mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • depatuxizumab mafodotin (ABT-414)"],"overall_status":"Completed","enrollment":" Enrollment 691","initiation":"Initiation: 01/04/2015","start_date":" 01/04/2015","primary_txt":" Primary completion: 04/04/2022","primary_completion_date":" 04/04/2022","study_txt":" Completion: 04/04/2022","study_completion_date":" 04/04/2022","last_update_posted":"2023-05-11"},{"id":"c02436a4-c327-4010-b280-df7280202ef3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05688605","created_at":"2023-01-18T14:59:52.605Z","updated_at":"2024-07-02T16:35:57.487Z","phase":"Phase 1/2","brief_title":"A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05688605","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-01-18"},{"id":"1bac34f5-57ad-4236-9cb3-6af869cb8fb2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05188209","created_at":"2022-01-12T15:53:51.462Z","updated_at":"2024-07-02T16:36:18.553Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.","source_id_and_acronym":"NCT05188209","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Meiyouheng (becotatug vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/24/2021","start_date":" 05/24/2021","primary_txt":" Primary completion: 03/21/2023","primary_completion_date":" 03/21/2023","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2022-01-12"},{"id":"b01bfdf1-e7ef-45d9-99fd-e4d3a84b363f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04838964","created_at":"2021-04-09T16:56:10.530Z","updated_at":"2024-07-02T16:36:19.035Z","phase":"Phase 2","brief_title":"A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer","source_id_and_acronym":"NCT04838964","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Meiyouheng (becotatug vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/28/2021","start_date":" 04/28/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2021-12-29"},{"id":"380a8863-daf3-4902-8a99-7907296c65b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03234712","created_at":"2021-01-18T15:59:05.637Z","updated_at":"2024-07-02T16:36:30.644Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)","source_id_and_acronym":"NCT03234712","lead_sponsor":"AbbVie","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e serclutamab talirine (ABBV-321)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 10/10/2017","start_date":" 10/10/2017","primary_txt":" Primary completion: 04/14/2021","primary_completion_date":" 04/14/2021","study_txt":" Completion: 04/14/2021","study_completion_date":" 04/14/2021","last_update_posted":"2021-05-06"},{"id":"e2d84696-64b6-495a-a910-c00f0219b393","acronym":"","url":"https://clinicaltrials.gov/study/NCT04868344","created_at":"2021-04-30T11:55:19.361Z","updated_at":"2024-07-02T16:36:30.948Z","phase":"Phase 1","brief_title":"A Study of MRG003 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04868344","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Meiyouheng (becotatug vedotin)"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 05/09/2018","start_date":" 05/09/2018","primary_txt":" Primary completion: 03/29/2021","primary_completion_date":" 03/29/2021","study_txt":" Completion: 03/29/2021","study_completion_date":" 03/29/2021","last_update_posted":"2021-04-30"},{"id":"e152b491-718a-41e4-b7c8-11bb4e0088bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04838548","created_at":"2021-04-09T17:54:50.218Z","updated_at":"2024-07-02T16:36:32.149Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04838548","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Meiyouheng (becotatug vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/04/2020","start_date":" 09/04/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 02/01/2023","study_completion_date":" 02/01/2023","last_update_posted":"2021-04-09"},{"id":"185a94cd-a349-4d14-992b-8bc9997567cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT02590263","created_at":"2021-01-18T12:34:17.164Z","updated_at":"2024-07-02T16:36:41.368Z","phase":"Phase 1/2","brief_title":"Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma","source_id_and_acronym":"NCT02590263","lead_sponsor":"AbbVie","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • depatuxizumab mafodotin (ABT-414)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 08/24/2015","start_date":" 08/24/2015","primary_txt":" Primary completion: 08/27/2020","primary_completion_date":" 08/27/2020","study_txt":" Completion: 08/27/2020","study_completion_date":" 08/27/2020","last_update_posted":"2020-09-03"},{"id":"be8c91be-539b-4b14-a9c2-42922b51a31c","acronym":"RTOG Foundation 3508","url":"https://clinicaltrials.gov/study/NCT02343406","created_at":"2021-01-18T11:08:20.656Z","updated_at":"2024-07-02T16:36:44.845Z","phase":"Phase 2","brief_title":"Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas","source_id_and_acronym":"NCT02343406 - RTOG Foundation 3508","lead_sponsor":"AbbVie","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • EGFRvIII mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • EGFRvIII mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lomustine • depatuxizumab mafodotin (ABT-414)"],"overall_status":"Completed","enrollment":" Enrollment 266","initiation":"Initiation: 02/17/2015","start_date":" 02/17/2015","primary_txt":" Primary completion: 06/24/2019","primary_completion_date":" 06/24/2019","study_txt":" Completion: 06/24/2019","study_completion_date":" 06/24/2019","last_update_posted":"2020-05-22"},{"id":"b45b7d7e-ea91-4655-9b1a-d36c708995e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03123952","created_at":"2021-01-18T15:23:35.910Z","updated_at":"2024-07-02T16:36:58.135Z","phase":"","brief_title":"Expanded Access to ABT-414","source_id_and_acronym":"NCT03123952","lead_sponsor":"AbbVie","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • EGFRvIII mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • EGFRvIII mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e depatuxizumab mafodotin (ABT-414)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2019-07-15"},{"id":"3ecdc7a7-9b27-4431-a827-8db514545d34","acronym":"","url":"https://clinicaltrials.gov/study/NCT01800695","created_at":"2021-01-18T07:58:14.654Z","updated_at":"2024-07-02T16:37:16.125Z","phase":"Phase 1","brief_title":"Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme","source_id_and_acronym":"NCT01800695","lead_sponsor":"AbbVie","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification • EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • depatuxizumab mafodotin (ABT-414)"],"overall_status":"Completed","enrollment":" Enrollment 202","initiation":"Initiation: 04/02/2013","start_date":" 04/02/2013","primary_txt":" Primary completion: 06/19/2017","primary_completion_date":" 06/19/2017","study_txt":" Completion: 06/19/2017","study_completion_date":" 06/19/2017","last_update_posted":"2017-11-21"},{"id":"fc2221ae-5b3f-4672-9045-b9945c90127f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01741727","created_at":"2021-01-18T07:37:25.208Z","updated_at":"2024-07-02T16:37:16.222Z","phase":"Phase 1/2","brief_title":"A Study of ABT-414 in Subjects With Solid Tumors","source_id_and_acronym":"NCT01741727","lead_sponsor":"AbbVie (prior sponsor, Abbott)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification • EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e depatuxizumab mafodotin (ABT-414)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2017-11-20"}]